One Platform. Multiple Product Opportunities.
The biphasic immediate-release / delayed-release delivery system provides a flexible formulation platform capable of supporting multiple therapeutic categories, differentiated products, and combination therapies.
Conventional short half-life drugs
Many high-value molecules suffer from pharmacokinetic limitations that constrain commercial success and patient outcomes.
Biphasic IR / DR delivery
A single oral dose delivers two precisely timed exposures — extending therapeutic coverage with simplified dosing.
Dual-peak exposure from a single dose
Where the platform creates value.
Seven illustrative application areas where the biphasic delivery platform may support differentiated product development.
Metabolic Disease & Diabetes
Particularly attractive for metabolic disease products where multiple therapies are frequently co-prescribed.
- Metformin combinations
- SGLT2 combinations
- GLP-1 adjunct therapies
- Diabetes management
- Metabolic syndrome
- Patient adherence optimization
Value-Added Generic Products
Transform commodity generic molecules into differentiated pharmaceutical products with new IP.
Lifecycle Management
Established brands use delivery innovation to create new commercial opportunities around products approaching patent expiry.
Combination Therapies
Innovative single-product combinations for therapies frequently prescribed together.
Cardiovascular Medicines
Applicability to medications requiring optimized exposure profiles and enhanced adherence.
CNS Therapies
Potential use in compounds where controlled exposure and simplified dosing may improve outcomes.
Anti-Infectives
Potential utility in maintaining therapeutic exposure while improving convenience and adherence.
Explore commercial opportunity across the platform.
From value-added generics to lifecycle management and 505(b)(2) pathways.